9-Methyl-β-carboline (9-Me-BC) is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

Also Available In:
Powder Option >>

SKU: ULN9MELS Categories: , Tags: , , ,


9-Methyl-β-carboline (9-Me-BC) Nootropic Liquid




CAS Number 2521-07-5
Other Names 2521-07-5, 9-methyl-9h-pyrido[3,4-b]indole, GC837J2CCJ
IUPAC Name 9-methylpyrido[3,4-b]indole
Molecular Formula C₁₂H₁₀N₂
Molecular Weight 182.22
Purity ≥99% Pure (LC-MS)
Liquid Availability 30mL liquid (50mg/mL, 1500mg bottle)
Powder Availability  1 gram, 5 grams
Gel Availability N/A
Storage Store in cool dry environment, away from direct sunlight.
Terms All products are for laboratory developmental research USE ONLY. Products are not for human consumption.


What is 9-ME-BC?

9-Methyl-𝛃-Carboline (9-Me-BC) is a potent nootropic that has shown promise in improving wakefulness, alertness, cognition, and mood. 9-Me-BC works by regulating the serotonergic and dopaminergic centers of the brain to decrease the reuptake of the two compounds. Evidence has shown that the increased levels of dopamine and serotonin help to greatly improve cognition and energy levels.

The primary active compound of 9-Me-BC is the 𝛃-Carboline. 𝛃-Carboline are alkaloids found in various insects, plants, mammals, and marine animals, and are known for its beneficial biochemical and pharmacological effects. 𝛃-Carboline compounds have been shown to insert themselves into DNA, interact with 5-hydroxy serotonin and benzodiazepine receptors, and inhibit the actions of CDK, topoisomerase, and monoamine oxidase. These properties indicate that the compounds have strong antioxidant and anti-inflammatory effects [1].


Main Research Findings

1. 9-Me-BC has been shown to enhance cognition by regulation of the dopaminergic system. The increased dopamine levels are strongly correlated to proliferation of dendrites and synapses

2. Additional research conducted on this compound has found that due the regulation of dopamine that occurs, 9-Me-BC could potentially be considered as a treatment for Parkinson’s Disease.


Selected Data

1. 7-week-old female Wistar rats were split into 4 experimental groups: non-injected animals, vehicle-injected animals, animals treated with 9-Me-BC for 5 days, and animals treated with 9-Me-BC for 10 days. The radial maze (RAM) test was used in order to measure changes in spatial learning. The first RAM test was conducted on day 0 before any treatment began while all following tests took place everyday approximately 3 hours after treatment [2].

2. Researchers Polanski et. Al have determined that 9-Me-BC has different beneficial properties that could support the claim that the compound is an effective treatment for Parkinson’s. This theory is based on the observed activity between 9-Me-BC and variables such as tyrosine hydroxylase and various immunoreactive neurons [3]



1. By decreasing the uptake of dopamine, which is known to be an important neurotransmitter, the compound is able to “relay its message” but is not reabsorbed by the synapse. This indicates that dopamine is active and present in the neuronal receptors for a longer period of time, thus leading to cognitive benefits. Results of the study conducted by found that after 7 days of treatment, rats given 9-Me-B for 10 days were already successful in completing the RAM test. However, there was no difference in the amount of errors made by the rats treated with a vehicle and the rats treated with 9-Me-BC for 5 days.

Figure 1: Decrease in errors on RAM test with administration of 9-Me-BC

The hippocampal tissue of the rats were examined further in order to measure changes in hippocampal dopamine levels and proliferation of synapses and dendrites. Again, there was no difference in the hippocampal dopamine levels of the rats administered 9-Me-BC for 5 days and to those given the vehicle. However, the rats given 9-Me-BC for 10 days saw a significant increase in hippocampal dopamine levels, almost double the levels of the non-injected animals.

Figure 2: Changes in dopamine levels based on the different experimental variables

It is important to note that when observing synaptic and dendritic proliferation, the only data compared was from the rats injected with a vehicle and those receiving 9-Me-BC for 10 days. That being said, there was drastic growth found in the synapses and dendrites of the rats receiving 9-Me-BC. The most significant changes were seen at 60 μm, 110 μm, and 160 μm [2].

Figure 3: Changes in the dendrites after administration of 9-Me-BC

2. 9-Me-BC is capable of increasing the release of tyrosine hydroxylase and its various transcription factors in immunoreactive neurons. This ultimately has a stimulatory effect on neurons of the dopaminergic system. Furthermore, 9-Me-BC has been shown to induce gene expression of different neurotrophic factors while also decreasing the rate of apoptosis cell signaling. This indicates that the compound has both protective and regenerative properties towards the dopaminergic neurons. 9-Me-BC can combat inflammation by inhibiting monoamine oxidase and the proliferation of microglia through the reduction of chemotactic cytokines.

Both the protection of the dopaminergic neurons and the overall anti-inflammatory properties the compound promotes is what leads researchers to believe 9-Me-BC could be used as a treatment for Parkinson’s Disease, considering dopamine and inflammation play a key role in the disease. However, further research is currently being conducted to hone in on the properties of the nootropic compound [3]



*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).


[1] Cao R, Peng W, Wang Z, Xu A. beta-Carboline alkaloids: biochemical and pharmacological functions. Curr Med Chem. 2007;14(4):479-500. doi: 10.2174/092986707779940998. PMID: 17305548.

[2] Gruss M, Appenroth D, Flubacher A, Enzensperger C, Bock J, Fleck C, Gille G, Braun K. 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. J Neurochem. 2012 Jun;121(6):924-31. doi: 10.1111/j.1471-4159.2012.07713.x. PMID: 22380576.

[3] Polanski W, Reichmann H, Gille G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? Expert Rev Neurother. 2011 Jun;11(6):845-60. doi: 10.1586/ern.11.1. PMID: 21651332.

9-Methyl-β-carboline (9-Me-BC) is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

*Note: A slight coloration shade may occur in between different batches; this is a normal occurrence for this research compound.




File Name View/Download